"10.1371_journal.pone.0063942","plos one","2013-08-28T00:00:00Z","Eric P Zorrilla; Amanda J Roberts; Jean E Rivier; George F Koob","Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, California, United States of America; Molecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, California, United States of America; The Clayton Foundation Laboratories for Peptide Biology and Structural Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, United States of America; Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America","Conceived and designed the experiments: EPZ GFK AJR. Performed the experiments: AJR. Analyzed the data: EPZ GFK AJR. Contributed reagents/materials/analysis tools: JER AJR. Wrote the paper: EPZ GFK AJR JER.","The authors have read the journals policy, and have the following conflicts: Drs. Zorrilla and Koob are coinventors on a patent for the composition and use of non-peptide selective CRF1 antagonists (US20100249138) and Dr. Rivier is the founder of Sentia Medical Sciences, Inc. Sentia has exclusive license from The Salk Institute to develop CRF1 and CRF2 peptide antagonists. Dr. Roberts has no potential conflicts of interest to disclose. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.",NA,NA,NA,"2013","08","Eric P Zorrilla","EPZ",4,TRUE,3,1,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
